FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
The FDA issued a final guidance document regarding post-approval pregnancy safety studies for drugs and biological products. The guidance provides recommendations on various methodologies for studying product safety when used during pregnancy in the post-market setting.
Manufacturers of drugs and biological products, specifically those involved in clinical development, post-market surveillance, and regulatory submissions for products used by populations of reproductive potential.
This guidance suggests a shift toward more standardized or diverse methodologies in post-approval safety data collection. For industry professionals, this likely implies that the FDA is refining its expectations for how pregnancy safety data is captured and analyzed. Regulatory teams may need to justify their choice of methodology (e.g., registries vs. other observational designs) more rigorously in post-marketing requirements (PMRs) or post-marketing commitments (PMCs).
Regulatory and clinical teams should evaluate current post-approval safety monitoring protocols against the new guidance to ensure methodologies for pregnancy data collection align with FDA expectations. Organizations should assess if existing registries or observational study designs require adjustment for upcoming or ongoing post-market commitments.
The U.S. Food and Drug Administration today issued a final guidance for industry, Postapproval Pregnancy Safety Studies, with recommendations on different methodologies that can be used in the postapproval setting to study the safety of drugs and biological products when used during pregnancy.
Open in openFDA / FDA.gov